35,66 €
Mehr erfahren.
- Herausgeber: Bentham Science Publishers
- Kategorie: Fachliteratur
- Sprache: Englisch
- Veröffentlichungsjahr: 2009
The immune system is highly complex, it senses foreign invaders, thus protecting the body. The adaptive arm of the immune system confers long-term protection, whereas the innate immune system confers immediate protection. In the case of the immune system, the pattern recognition receptors offer various modes of sensing the molecular patterns associated with pathogens.
Toll-like receptors (TLRs) are important mediators of inflammatory pathways in the gut which play a major role in mediating the immune responses towards a wide variety of pathogen-derived ligands and link adaptive immunity with the innate immunity.
This book covers the role of TLRs in several vector-borne Diseases. Starting with an introduction to these diseases, the book explains the different types of receptors involved in these diseases. The diseases are then covered in separate chapters, including: malaria, lymphatic filariasis, visceral leishmaniasis, dengue fever, chikungunya, West Nile fever, and Japanese encephalitis.
The book is a handy reference for researchers and trainees involved in clinical medicine and infection control. It can also serve as supplementary reading material for Students undertaking courses in biotechnology, public health, entomology, immunology, epidemiology, and life sciences.
Das E-Book können Sie in Legimi-Apps oder einer beliebigen App lesen, die das folgende Format unterstützen:
Seitenzahl: 157
Ähnliche
BENTHAM SCIENCE PUBLISHERS LTD.
End User License Agreement (for non-institutional, personal use)
This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“Work”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.
Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [email protected].
Usage Rules:
All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.Disclaimer:
Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.
Limitation of Liability:
In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.
General:
Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.Bentham Science Publishers Pte. Ltd. 80 Robinson Road #02-00 Singapore 068898 Singapore Email: [email protected]
FOREWORD
This topic is appropriate when we talk about the control of vector-borne diseases as a top priority in the world. Vector-borne diseases are a huge public health problem all over the world. Vectors are organisms that transmit pathogens from infected human to animal or from animal to human, accounting for 17% of Vector-borne diseases (VBDs). Vector-borne diseases such as Malaria, Dengue, Chikungunya, Human African Trypanosomiasis, Leishmaniasis, Japanese encephalitis, Chaga’s diseases, Yellow fever, Leishmaniasis, and Onchocerciasis have become major public health concern affecting more than one billion cases and one million deaths globally. There is an urgent need to control these challenges and state of art techniques and science and technology will take it forward. Toll-like receptors are the primary pattern recognition receptors in the human systems and in eliciting innate immune signalling. Cytokines produced through toll-like receptors activation act as a bridge to elicit an adaptive immune response as well. I appreciate this book's title on toll-like receptors in vector-borne diseases as this book can be read by many researchers, industry persons, policymakers, and academicians and can cater to the needs of the research on these vector-borne diseases.
I convey my best wishes to the editor and hope this book will be a great success.
PREFACE
Organisms/animals that transmit diseases are called vectors. They cause serious health problems to the human population such as illness and death. Famous vectors that cause diseases include fleas, ticks, mites, and mosquitos. Mostly, the vectors are invertebrate arthropods and non-living fomites. A disease that can be transmitted from an arthropod or a fomite to a human or animal or plant is called a vector-borne disease (VBDs). Vectors are able to carry and transmit various infectious organisms such as parasites, bacteria and viruses. Vector-borne diseases in a given country affect the socio-economic status and have a huge impact on the Global disease burden.
Ironically, despite decades of research on VBDs, still much remains to be discovered on the complicated relationships between vector, host, and pathogen in their internal environment. The emergence of new diseases such as Zika possess more questions on the complicity of host-pathogen-vector interaction. Any effective vaccine/intervention/ depends on the complete information on the molecules that perform interaction between host-pathogen-vector. Hence, a complete understanding is very much essential. Vector-borne diseases are a threat to the community worldwide. Each year 2.5 billion people in over 100 countries (WHO reports) die of such diseases. Brain inflammation, coma, cerebral leakage, meningitis, neuronal and glial cell degeneration, endothelial dysfunction, blood-brain barrier leakage, and disturbance in Cerebro Spinal Fluid (CSF) circulation have all been noted in various vector-borne diseases such as dengue, Chikungunya, Malaria, West Nile fever, Filariasis and Japanese encephalitis (JE) . I wish our readers can be satisfied with many questions which they feel excited to find the answer for research questions on the etiology of neurological sequale of vector-borne diseases in this book.
Introduction to Vector Borne Diseases
Abstract
Vector-borne diseases(VBDs) are reported to represent amount 17% of all infectious diseases. The geographical distribution of vectors depends upon various climatic factors, and social factors. In the recent past, the spread of VBDs across the world is so rapid that it is associated with a change in climatic factors, global warming, travel and trade, unplanned urbanization, deforestation etc. Amongst the vector-borne diseases notable is West Nile fever (WNF) caused by West Nile Virus (WNV). WNF belongs to the family of Flaviviridae, which is part of the Japanese encephalitis antigenic group. WNV is transmitted from infected birds to human beings by mosquito bites. WNV is readily reported in Africa, Europe, the Middle East, North America and West Asia. Looking at the history, WNV was first isolated in a woman in the West Nile district of Uganda in 1937. It was identified in birds (crows and columbiformes) in the Nile delta region in 1953. Over the past 50 years, human cases of WNV have been reported in various countries.
INTRODUCTION
Vector-borne diseases(VBD)s are reported to represent amount 17% of all infectious diseases. The geographical distribution of vectors depends upon various climatic factors, and social factors. In the recent past, the spread of VBDs across the world is so rapid that it is associated with change in climatic factors, global warming, travel and trade, unplanned urbanization, deforestation etc.
Amongst the vector-borne diseases notable is West Nile fever (WNF) caused by West Nile Virus (WNV). WNF belongs to the family of Flaviviridae which is part of the Japanese encephalitis antigenic group. WNV is transmitted from infected birds to human beings by mosquito bites. WNV is readily reported in Africa, Europe, the Middle East, North America and West Asia. Looking at the history, WNV was first isolated in a woman in the West Nile district of Uganda in 1937. It was identified in birds (crows and columbiformes) in the Nile delta region in 1953. Over the past 50 years, human cases of WNV are reported in various countries.
CHIKUNGUNYA
For joint pain caused by chikyngunya medicines such as nacproxen, ibuprofen, and acetaminophen can be tried. Joint pain caused by chikungunya persists for several weeks even after the fever has been cured. As of now there is no vaccine for the treatment of chikyngunya and no antiviral treatment is available. Using insect repellent, sleeping under the mosquito net, breeding places control, wearing full clothes can be used as preventive options for chikungunya.The word Chikungunya is coined from the makondae language which means bends up or contorted “walk with bent over”. This disease was reported in 1952 after an outbreak in Makonde Plateau in eastern Tanzania. Initially, this disease was reported seen in Africa and Asia but after 2007, it is also reported to occur from various European countries as well. Currently, more than 60 countries are reporting this fever. The mosquitos which spread Chikungunya fever are day bitters, they spread the disease from one infected person to another normal person when they bite. Symptoms last for 2 to 12 days after the infection begin.The fever is divided into acute and chronic phases,in which the acute phase is known as the febrile phase. Fever is the main symptom in the acute phase and in the chronic phase and is characterised by inflammatory joint pain in some patients up to years it can extend.
Chikungunya fever is a viral disease like WNV that belongs to the genus Alphavirus from the family of Togaviridae. Chikungunya fever is transmitted to human beings by the infected mosquito of Ad aegypti, and Ae albopictus. Chikungunya fever was first described during an outbreak in southern Tanzania in 1952. At present, CHIKV is reported in 50 countries.
LEISHMANIASIS
Leishmaniasis is a protozoan parasitic infection that is transmitted to human beings through the bite of an infected female sandfly. There are three types of Lieshmaniasis, cutaneous, visceral and mucocutaneous. Amongst these, Visceral Lieshmaniasis is progressing rapidly in east Africa with the highest mortality and morbidity. Visceral leishmaniasis if not treated can lead to high rates of mortality and epidemics. Cutaneous leishmaniasis is observed in Afghanistan and Syrian Republic. According to WHO, in 2014, more than 90% of new cases were reported to WHO from six countries: Brazil, Ethiopia, India, Somalia, South Sudan and Sudan. Strikingly, a vast major case of cutaneous Leishmaniasis is reported from Pakistan, Peru, Saudi Arabia and the Syrian Arab Republic, Afghanistan, Algeria, Brazil, Colombia, and the Islamic Republic of Iran. Mucocutaneous leishmaniasis is reported in Bolivia, Brazil and Peru, somewhere around 90%. Surprisingly, the control programs for Kala-azar are successful in South-East Asia Region (SEARO) countries.
MALARIA
Malaria is caused by one of four species of the Plasmodium parasite transmitted by female Anopheles spp mosquitoes. Malaria vector control methods have been proven successful in the past which is one of the deadliest vector-borne diseases. Malaria is one of the life-threatening diseases. According to WHO, in 2015 an estimated 212 million cases of malaria occurred worldwide and 429,000 people died, mostly children in the African Region. According to CD, about 1,500 cases of malaria are diagnosed in the United States each year. In India, malaria is a well-known reported public health problem. According to National Vector Bone Diseases Control Programme (NVBDCP), in 2017, among the total of 1,98, 303 cases of malaria, it was reported that Plasmodium falsiparum is seen in 1,42,152 cases.
DENGUE
Dengue is the most important arboviral human disease,Ae. aegypti, and Ae. albopictus, the dengue vectors can be easily influenced by changing humidity, temperature, rainfall, degree of urbanization, and control measures taken by various countries. According to WHO before 1970, dengue was reported in nine countries only, however, now the spread is so rapid that dengue is reported in more than 100 countries, and such a situation is very alarming. In 2016, 1,29,166 cases have been reported in India by the National Vector Borne Disease Control Programme (NVBDCP).
JE was first reported in Uttar Pradesh, the main JE epidemic area in the northern state of India in 1978. The Cx.vishnui subgroup, and the Cx. tritaeniorhynchus, Cx. seudovishnui and Anopheles subpictus, were the main mosquito vectors and secondary vectors in India. In 2016, a total of 1676 cases of JE is reported from India according to NVBDCP. The virus is a single-stranded RNA virus.Pigs and birds are the intermediate hosts of the virus. Human beings are considered dead-end hosts. Upon bite of the infection the virus replicates in the lymph nodes and then viremia develops. After this, the virus enters the central nervous system to effect. The virus has the capacity to alter neurodevelopment also. There is no effective treatment for this viral infection but there can be supportive care and fluids given. Southeast Asian nations and west pacific nations are at higher risk of reporting the cases. Avoiding mosquito bites is the best prevention for this disease.
During rainy seasons the mosquitoes breed a lot and thus increase the chances of disease spread. The JE virus belongs to the flavivirus which is related to dengue virus, West nile virus and yellow fever. More than 3 billion people are risk for getting the JE disease. In Japan in 1971 the first case of dengue fever is reported. The incubation period of the virus ranges from four to fourteen days.
The virus was first isolated in 1935, however until now the origin of the virus remains sceptical. Travelling to JE endemic areas can increase the susceptibility of the person to the virus. Immunization can be done to prevent the spread of the virus. The types of vaccines available for JE diseases are: Live recombinant vaccines, live attenuated vaccines, inactivated Vero cell derived vaccines and inactivated mouse brain derived vaccines. The virus spreads only through the bite of the mosquito not from person to person. There is no specific medicine or treatment for this virus but immunization can help and also avoid the mosquito bites by taking preventing measures can help the people in getting the disease. Some animals like birds and pigs can serve as large reservoir of the virus for the spread of the disease through the mosquito bite. The best way to prevent the disease is to wear long sleeved shirts and pants, DEET insect repellents can be used. Early evening walks should be avoided in endemic areas as this time is the greatest activity of the JE mosquitoes. There are five genotypes of Japanese encephalitis virus it has 11 KB single stranded RNA which is of 3800 KD.The infected people first report the non –specific febrile illness followed by lose of consciousness and occurring of convulsions or seizures. Neurological sequel is reported in admitted patients , however around 30% of patients die of the virus induced illness.
CONCLUDING REMARKS
Vector-borne diseases are a public health threat. Increasing cases of these diseases year by year in the world pose a threat to human health and well-being. Mosquitoes such as Ae.aegypti, and Ae.albopictus spread dengue and CHICKV. The spread of dengue is so rapid that it is reported more than in 100 countries.WNV is reported in Africa, Europe, the middle east, North America and West Asia. Looking at the history, WNV was first isolated in a woman in the west Nile district of Uganda in 1937. All these historical events warn that VBDs are not going to be restricted in one place but going to spread to so many non-endemic areas and hence their control becomes a priority task.
